IL153374A - Preparations and methods for coating medical devices - Google Patents

Preparations and methods for coating medical devices

Info

Publication number: IL153374A
Authority: IL; Israel
Prior art keywords: coated; coating; microspheres; nanospheres; compositions
Prior art date: 1996-06-12

Application number

IL153374A

Other languages

English (en)

Hebrew (he)

Original Assignee

Univ Michigan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-12

Filing date

1997-06-11

Publication date

2007-07-24

1997-06-11 Application filed by Univ Michigan filed Critical Univ Michigan

2007-07-24 Publication of IL153374A publication Critical patent/IL153374A/en

Links

238000000576 coating method Methods 0.000 title description 109
238000000034 method Methods 0.000 title description 108
239000011248 coating agent Substances 0.000 title description 95
239000000203 mixture Substances 0.000 title description 70
239000008177 pharmaceutical agent Substances 0.000 claims description 155
102000039446 nucleic acids Human genes 0.000 claims description 110
108020004707 nucleic acids Proteins 0.000 claims description 110
150000007523 nucleic acids Chemical class 0.000 claims description 109
239000004005 microsphere Substances 0.000 claims description 98
239000002077 nanosphere Substances 0.000 claims description 97
108090000623 proteins and genes Proteins 0.000 claims description 94
239000000839 emulsion Substances 0.000 claims description 54
239000011159 matrix material Substances 0.000 claims description 52
230000029663 wound healing Effects 0.000 claims description 37
239000007943 implant Substances 0.000 claims description 33
239000000725 suspension Substances 0.000 claims description 28
208000027418 Wounds and injury Diseases 0.000 claims description 27
206010052428 Wound Diseases 0.000 claims description 26
229920002988 biodegradable polymer Polymers 0.000 claims description 19
239000004621 biodegradable polymer Substances 0.000 claims description 19
238000001727 in vivo Methods 0.000 claims description 18
210000004027 cell Anatomy 0.000 description 72
229920000642 polymer Polymers 0.000 description 65
239000008199 coating composition Substances 0.000 description 61
108020004414 DNA Proteins 0.000 description 58
102000004169 proteins and genes Human genes 0.000 description 58
210000001519 tissue Anatomy 0.000 description 49
230000001225 therapeutic effect Effects 0.000 description 36
230000008439 repair process Effects 0.000 description 33
-1 sucrose fatty esters Chemical class 0.000 description 31
150000002118 epoxides Chemical class 0.000 description 29
239000003960 organic solvent Substances 0.000 description 27
239000002904 solvent Substances 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
230000008901 benefit Effects 0.000 description 20
229920001610 polycaprolactone Polymers 0.000 description 19
238000013268 sustained release Methods 0.000 description 19
239000008346 aqueous phase Substances 0.000 description 18
239000003795 chemical substances by application Substances 0.000 description 18
238000013270 controlled release Methods 0.000 description 18
230000014509 gene expression Effects 0.000 description 18
239000000443 aerosol Substances 0.000 description 17
230000002209 hydrophobic effect Effects 0.000 description 17
239000000047 product Substances 0.000 description 17
238000001415 gene therapy Methods 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
125000000524 functional group Chemical group 0.000 description 15
229920001223 polyethylene glycol Polymers 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
230000002062 proliferating effect Effects 0.000 description 15
239000012730 sustained-release form Substances 0.000 description 15
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 14
239000002202 Polyethylene glycol Substances 0.000 description 14
239000003995 emulsifying agent Substances 0.000 description 14
239000012074 organic phase Substances 0.000 description 14
230000014616 translation Effects 0.000 description 14
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 13
230000008569 process Effects 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
229920001577 copolymer Polymers 0.000 description 12
230000003834 intracellular effect Effects 0.000 description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
238000013519 translation Methods 0.000 description 12
108090000994 Catalytic RNA Proteins 0.000 description 11
102000053642 Catalytic RNA Human genes 0.000 description 11
102000053602 DNA Human genes 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
230000035876 healing Effects 0.000 description 11
239000002245 particle Substances 0.000 description 11
108091092562 ribozyme Proteins 0.000 description 11
239000013598 vector Substances 0.000 description 11
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
229920000570 polyether Polymers 0.000 description 10
230000002459 sustained effect Effects 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
108020004491 Antisense DNA Proteins 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
229920001451 polypropylene glycol Polymers 0.000 description 9
210000002027 skeletal muscle Anatomy 0.000 description 9
238000000527 sonication Methods 0.000 description 9
108020005544 Antisense RNA Proteins 0.000 description 8
239000004599 antimicrobial Substances 0.000 description 8
239000000227 bioadhesive Substances 0.000 description 8
229920001400 block copolymer Polymers 0.000 description 8
230000006378 damage Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
229920001983 poloxamer Polymers 0.000 description 8
239000000126 substance Substances 0.000 description 8
238000012546 transfer Methods 0.000 description 8
108020004774 Alkaline Phosphatase Proteins 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
239000004721 Polyphenylene oxide Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 7
239000003054 catalyst Substances 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
229920006030 multiblock copolymer Polymers 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
230000003578 releasing effect Effects 0.000 description 7
238000001878 scanning electron micrograph Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
229920000428 triblock copolymer Polymers 0.000 description 7
238000003260 vortexing Methods 0.000 description 7
102000002260 Alkaline Phosphatase Human genes 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
229940126639 Compound 33 Drugs 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 6
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 6
239000003242 anti bacterial agent Substances 0.000 description 6
239000003816 antisense DNA Substances 0.000 description 6
239000000919 ceramic Substances 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
150000001875 compounds Chemical group 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
239000004310 lactic acid Substances 0.000 description 6
235000014655 lactic acid Nutrition 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000003380 propellant Substances 0.000 description 6
231100000241 scar Toxicity 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000011477 surgical intervention Methods 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
239000013603 viral vector Substances 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
102000003982 Parathyroid hormone Human genes 0.000 description 5
108090000445 Parathyroid hormone Proteins 0.000 description 5
229920000954 Polyglycolide Polymers 0.000 description 5
239000003899 bactericide agent Substances 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
239000003184 complementary RNA Substances 0.000 description 5
230000001804 emulsifying effect Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
239000000199 parathyroid hormone Substances 0.000 description 5
229960001319 parathyroid hormone Drugs 0.000 description 5
229920002635 polyurethane Polymers 0.000 description 5
239000004814 polyurethane Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
210000001124 body fluid Anatomy 0.000 description 4
239000010839 body fluid Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
239000006184 cosolvent Substances 0.000 description 4
238000007598 dipping method Methods 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000000399 orthopedic effect Effects 0.000 description 4
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
229920000233 poly(alkylene oxides) Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000007921 spray Substances 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
208000037816 tissue injury Diseases 0.000 description 4
239000010936 titanium Substances 0.000 description 4
229910052719 titanium Inorganic materials 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
229920001651 Cyanoacrylate Polymers 0.000 description 3
229920005682 EO-PO block copolymer Polymers 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
239000004372 Polyvinyl alcohol Substances 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
150000002009 diols Chemical class 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
229920001519 homopolymer Polymers 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
229920002451 polyvinyl alcohol Polymers 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
238000005507 spraying Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
238000005199 ultracentrifugation Methods 0.000 description 3
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 3
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
101000762424 Mus musculus Bone morphogenetic protein 4 Proteins 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
229920002732 Polyanhydride Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
229910007607 Zn(BF4)2 Inorganic materials 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000004479 aerosol dispenser Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940127218 antiplatelet drug Drugs 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
230000001680 brushing effect Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000002327 cardiovascular agent Substances 0.000 description 2
229940125692 cardiovascular agent Drugs 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
239000000515 collagen sponge Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
229940125878 compound 36 Drugs 0.000 description 2
238000011109 contamination Methods 0.000 description 2
NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 2
JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 2
102000026898 cytokine binding proteins Human genes 0.000 description 2
108091008470 cytokine binding proteins Proteins 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000000151 deposition Methods 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
XRWMGCFJVKDVMD-UHFFFAOYSA-M didodecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC XRWMGCFJVKDVMD-UHFFFAOYSA-M 0.000 description 2
229940113088 dimethylacetamide Drugs 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000002616 endonucleolytic effect Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
229960002247 lomustine Drugs 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
108010031345 placental alkaline phosphatase Proteins 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
239000004632 polycaprolactone Substances 0.000 description 2
229920000647 polyepoxide Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000012798 spherical particle Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
229940078499 tricalcium phosphate Drugs 0.000 description 2
229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
239000008307 w/o/w-emulsion Substances 0.000 description 2
239000011701 zinc Substances 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
FRCHKSNAZZFGCA-UHFFFAOYSA-N 1,1-dichloro-1-fluoroethane Chemical compound CC(F)(Cl)Cl FRCHKSNAZZFGCA-UHFFFAOYSA-N 0.000 description 1
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
JQZFYIGAYWLRCC-UHFFFAOYSA-N 1-chloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)(F)Cl JQZFYIGAYWLRCC-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
229910017048 AsF6 Inorganic materials 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
102000000905 Cadherin Human genes 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
VKPYUUBEDXIQIB-QBPWRKFFSA-N Ciprostene Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@]21C VKPYUUBEDXIQIB-QBPWRKFFSA-N 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
206010011044 Corneal scar Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
101100478056 Dictyostelium discoideum cotE gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010066486 EGF Family of Proteins Proteins 0.000 description 1
102000018386 EGF Family of Proteins Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
241000175212 Herpesvirales Species 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000035478 Interatrial communication Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
XAFYCPTXURWXGH-UHFFFAOYSA-N P(O)(O)(O)=S.P(O)(O)=O Chemical compound P(O)(O)(O)=S.P(O)(O)=O XAFYCPTXURWXGH-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
229920002614 Polyether block amide Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000019361 Syndecan Human genes 0.000 description 1
108050006774 Syndecan Proteins 0.000 description 1
102000006463 Talin Human genes 0.000 description 1
108010083809 Talin Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
102000003970 Vinculin Human genes 0.000 description 1
108090000384 Vinculin Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
108091027569 Z-DNA Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
HSTJJKALJLWLBR-UHFFFAOYSA-N aminophosphonic acid;2-methoxyethoxyphosphonamidic acid Chemical compound NP(O)(O)=O.COCCOP(N)(O)=O HSTJJKALJLWLBR-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940072049 amyl acetate Drugs 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002965 anti-thrombogenic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940052651 anticholinergic tertiary amines Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
101150036080 at gene Proteins 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
208000013914 atrial heart septal defect Diseases 0.000 description 1
206010003664 atrial septal defect Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
108010079292 betaglycan Proteins 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000002639 bone cement Substances 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical class FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000001273 butane Substances 0.000 description 1
229940067596 butylparaben Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
210000001043 capillary endothelial cell Anatomy 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000002729 catgut Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
230000008859 change Effects 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
229950009522 ciprostene Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000013601 cosmid vector Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
IDASTKMEQGPVRR-UHFFFAOYSA-N cyclopenta-1,3-diene;zirconium(2+) Chemical compound [Zr+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 IDASTKMEQGPVRR-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229920000359 diblock copolymer Polymers 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
229950010048 enbucrilate Drugs 0.000 description 1
229940046085 endocrine therapy drug gonadotropin releasing hormone analogues Drugs 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
230000000369 enteropathogenic effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
QPADNTZLUBYNEN-UHFFFAOYSA-N etallobarbital Chemical compound C=CCC1(CC)C(=O)NC(=O)NC1=O QPADNTZLUBYNEN-UHFFFAOYSA-N 0.000 description 1
JDVIRCVIXCMTPU-UHFFFAOYSA-N ethanamine;trifluoroborane Chemical compound CCN.FB(F)F JDVIRCVIXCMTPU-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
102000028718 growth factor binding proteins Human genes 0.000 description 1
108091009353 growth factor binding proteins Proteins 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
229940113174 imidurea Drugs 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007735 ion beam assisted deposition Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
108010021336 lanreotide Proteins 0.000 description 1
229960002437 lanreotide Drugs 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000004807 localization Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
ZFIVKAOQEXOYFY-ZXZARUISSA-N meso-diepoxybutane Chemical compound C1O[C@H]1[C@H]1OC1 ZFIVKAOQEXOYFY-ZXZARUISSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000007769 metal material Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
108010065781 myosin light chain 2 Proteins 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000000278 osteoconductive effect Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008249 pharmaceutical aerosol Substances 0.000 description 1
239000008040 pharmaceutical emulsifying agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
229920001484 poly(alkylene) Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920000223 polyglycerol Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
229920000166 polytrimethylene carbonate Polymers 0.000 description 1
229920001290 polyvinyl ester Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940070353 protamines Drugs 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
UKHVLWKBNNSRRR-TYYBGVCCSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C/C=C/Cl)C3 UKHVLWKBNNSRRR-TYYBGVCCSA-M 0.000 description 1
229940096792 quaternium-15 Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
102000035025 signaling receptors Human genes 0.000 description 1
108091005475 signaling receptors Proteins 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
239000003356 suture material Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical class BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
OFBPGACXRPVDQW-UHFFFAOYSA-N thiirane 1,1-dioxide Chemical compound O=S1(=O)CC1 OFBPGACXRPVDQW-UHFFFAOYSA-N 0.000 description 1
PCYCVCFVEKMHGA-UHFFFAOYSA-N thiirane 1-oxide Chemical compound O=S1CC1 PCYCVCFVEKMHGA-UHFFFAOYSA-N 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
239000011135 tin Substances 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
229960000363 trapidil Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
230000002883 vasorelaxation effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000003130 ventricular septal defect Diseases 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
229960004854 viral vaccine Drugs 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/86—Pins or screws or threaded wires; nuts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
- A61F2002/30064—Coating or prosthesis-covering structure made of biodegradable material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/3084—Nanostructures
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00017—Iron- or Fe-based alloys, e.g. stainless steel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00023—Titanium or titanium-based alloys, e.g. Ti-Ni alloys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/0097—Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/931—Medical device coating

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Surgery (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Materials Engineering (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Paints Or Removers (AREA)

IL153374A 1996-06-12 1997-06-11 Preparations and methods for coating medical devices IL153374A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/662,341 US6143037A (en)	1996-06-12	1996-06-12	Compositions and methods for coating medical devices

Publications (1)

Publication Number	Publication Date
IL153374A true IL153374A (en)	2007-07-24

Family

ID=24657324

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL153374A IL153374A (en)	1996-06-12	1997-06-11	Preparations and methods for coating medical devices
IL12744697A IL127446A (en)	1996-06-12	1997-06-11	Compositions and methods for coating medical devices

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL12744697A IL127446A (en)	1996-06-12	1997-06-11	Compositions and methods for coating medical devices

Country Status (7)

Country	Link
US (2)	US6143037A (2)
EP (1)	EP0910301A4 (2)
JP (2)	JP2000512519A (2)
AU (1)	AU715339B2 (2)
CA (1)	CA2257976C (2)
IL (2)	IL153374A (2)
WO (1)	WO1997047254A1 (2)

Families Citing this family (318)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143037A (en) *	1996-06-12	2000-11-07	The Regents Of The University Of Michigan	Compositions and methods for coating medical devices
US6387700B1 (en)	1996-11-04	2002-05-14	The Reagents Of The University Of Michigan	Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
GB2325934A (en) *	1997-06-03	1998-12-09	Polybiomed Ltd	Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
US6433154B1 (en) *	1997-06-12	2002-08-13	Bristol-Myers Squibb Company	Functional receptor/kinase chimera in yeast cells
US6569688B2 (en) *	1997-08-26	2003-05-27	Technion Research & Development Foundation Ltd.	Intravascular apparatus method
US6775574B1 (en) *	1997-11-07	2004-08-10	Medtronic, Inc.	Method and system for myocardial infarction repair
US6465015B1 (en) *	1998-02-24	2002-10-15	Arch Chemicals, Inc.	Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6395253B2 (en)	1998-04-23	2002-05-28	The Regents Of The University Of Michigan	Microspheres containing condensed polyanionic bioactive agents and methods for their production
WO1999055396A1 (en)	1998-04-27	1999-11-04	Surmodics, Inc.	Bioactive agent release coating
US7427602B1 (en)	1998-05-13	2008-09-23	The Regents Of The University Of Michigan	Sustained DNA delivery from structural matrices
JP2002515514A (ja) *	1998-05-21	2002-05-28	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの局所送逹のための組成物及び方法
FR2779340B1 (fr) *	1998-06-04	2000-12-29	Delab	Dispositif intraluminal implantable
US6464999B1 (en) *	1998-06-17	2002-10-15	Galt Incorporated	Bioadhesive medical devices
US6627209B2 (en) *	1998-08-03	2003-09-30	W. Jerry Easterling	Surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents
JP4854114B2 (ja)	1998-09-11	2012-01-18	シュミドマイヤー，ゲルハルド	生物学的に活性なインプラント
US20030099682A1 (en) *	1998-11-20	2003-05-29	Francis Moussy	Apparatus and method for control of tissue/implant interactions
US6540780B1 (en)	1998-11-23	2003-04-01	Medtronic, Inc.	Porous synthetic vascular grafts with oriented ingrowth channels
AU3471400A (en) *	1999-01-19	2000-08-07	Children's Hospital Of Philadelphia, The	Compositions and methods for controlled delivery of virus vectors
US6682724B2 (en)	1999-02-23	2004-01-27	Arch Chemcials, Inc.	Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6767928B1 (en) *	1999-03-19	2004-07-27	The Regents Of The University Of Michigan	Mineralization and biological modification of biomaterial surfaces
ES2199815T3 (es) *	1999-03-19	2004-03-01	The Regents Of The University Of Michigan	Mineralizacion y desarrollo celular supeerficial sobre biomateriales.
AU3957400A (en)	1999-04-16	2000-11-02	Novo Nordisk A/S	Dry, mouldable drug formulation
US6469132B1 (en) *	1999-05-05	2002-10-22	Mcgill University	Diblock copolymer and use thereof in a micellar drug delivery system
JP2003502350A (ja) *	1999-06-22	2003-01-21	リサーチディベロップメントファンデーション	傷癒合促進用促進傷被覆材
AU730929B2 (en) *	1999-07-06	2001-03-22	Nestec S.A.	Composition and method for prolonging the useful life of enteral feeding tubes
US6770740B1 (en)	1999-07-13	2004-08-03	The Regents Of The University Of Michigan	Crosslinked DNA condensate compositions and gene delivery methods
US6554857B1 (en) *	1999-07-20	2003-04-29	Medtronic, Inc	Transmural concentric multilayer ingrowth matrix within well-defined porosity
US6702848B1 (en)	1999-07-20	2004-03-09	Peter Paul Zilla	Foam-type vascular prosthesis with well-defined anclio-permissive open porosity
AU6517900A (en) *	1999-08-03	2001-02-19	Smith & Nephew, Inc.	Controlled release implantable devices
US6790228B2 (en)	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US7807211B2 (en)	1999-09-03	2010-10-05	Advanced Cardiovascular Systems, Inc.	Thermal treatment of an implantable medical device
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20020006664A1 (en) *	1999-09-17	2002-01-17	Sabatini David M.	Arrayed transfection method and uses related thereto
US9616150B2 (en) *	1999-10-29	2017-04-11	Children's Hospital Los Angeles	Bone hemostasis method and materials
US7109024B2 (en) *	1999-11-15	2006-09-19	Dr. Chip Biotechnology Inc.	Biomolecule-bound substrates
US6887842B1 (en) *	1999-11-19	2005-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7838007B2 (en) *	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating mammary gland disorders
JP4751556B2 (ja)	2000-02-28	2011-08-17	ジーンシーグス，インコーポレイテッド	ナノカプセルカプセル化システムおよび方法
ATE362382T1 (de) *	2000-03-15	2007-06-15	Orbusneich Medical Inc	Beschichtung welche ein anhaften von endothelzellen stimuliert
US8574146B2 (en)	2000-04-14	2013-11-05	Attenuex Technologies, Inc.	Implant with high vapor pressure medium
US10327880B2 (en)	2000-04-14	2019-06-25	Attenuex Technologies, Inc.	Attenuation device for use in an anatomical structure
ATE405352T1 (de)	2000-05-16	2008-09-15	Univ Minnesota	Partikelerzeugung für einen hohen massedurchsatz mit einer mehrfachdüsenanordnung
DE10025803A1 (de) *	2000-05-24	2001-12-20	Jms Co Ltd	Polymeroberfläche mit biologisch aktiven Eigenschaften und Verfahren zu ihrer Herstellung
US6719991B2 (en) *	2000-06-09	2004-04-13	Baylor College Of Medicine	Combination of antimicrobial agents and bacterial interference to coat medical devices
ATE355813T1 (de) *	2000-07-14	2007-03-15	Novo Nordisk As	Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
US6669959B1 (en) *	2000-07-18	2003-12-30	Aeropharm Technology Incorporated	Modulated release particles for lung delivery
JP2002035109A (ja) *	2000-07-21	2002-02-05	Tadashi Kokubo	抗血栓性材料及びその製造方法
BR0114909A (pt)	2000-10-26	2004-02-03	Alza Corp	Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
US20040241211A9 (en) *	2000-11-06	2004-12-02	Fischell Robert E.	Devices and methods for reducing scar tissue formation
US6534693B2 (en) *	2000-11-06	2003-03-18	Afmedica, Inc.	Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) *	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
US20020082222A1 (en)	2000-11-30	2002-06-27	Shapira Nathan Andrew	Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US6812217B2 (en) *	2000-12-04	2004-11-02	Medtronic, Inc.	Medical device and methods of use
DE10113108B4 (de) *	2001-03-15	2007-07-26	Dot Gmbh	Wirkstoffhaltige Calciumphosphat-Materialien
EP2226018A1 (en) *	2001-03-26	2010-09-08	Tyco Healthcare Group, LP	Oil coated sutures
US6656506B1 (en)	2001-05-09	2003-12-02	Advanced Cardiovascular Systems, Inc.	Microparticle coated medical device
US7247338B2 (en)	2001-05-16	2007-07-24	Regents Of The University Of Minnesota	Coating medical devices
GB0113697D0 (en) *	2001-06-06	2001-07-25	Smith & Nephew	Fixation devices for tissue repair
US7544670B2 (en)	2001-06-14	2009-06-09	The Regents Of The University Of California	HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing
WO2002102982A2 (en) *	2001-06-14	2002-12-27	Regents Of The University Of California	Hoxd3 compositions ad methods for improved wound healing
US20040142013A1 (en) *	2001-07-13	2004-07-22	Flow Focusing, Inc.	Implantable orthopedic surgical devices with controlled release antimicrobial component
US20030055075A1 (en) *	2001-07-13	2003-03-20	Rubsamen Reid M.	Programmable controlled release injectable opioid formulation
US20060263401A1 (en) *	2001-07-13	2006-11-23	Flow Focusing, Inc.	Formulation and Method for Preventing Infection
US20070254008A1 (en) *	2001-07-13	2007-11-01	Flow Focusing, Inc.	Antibiotic formulation and method of treatment
US20070254009A1 (en) *	2001-07-13	2007-11-01	Flow Focusing, Inc.	Antibiotic/bone morphogenic protein formulation and method of treatment
US6913626B2 (en) *	2001-08-14	2005-07-05	Mcghan Jim J.	Medical implant having bioabsorbable textured surface
US6641611B2 (en)	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
ATE295155T1 (de) *	2001-10-05	2005-05-15	Surmodics Inc	Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
US20090131990A1 (en) *	2001-10-18	2009-05-21	Kishore Tipirneni	Bone screw system and method
US20090254129A1 (en) *	2007-04-30	2009-10-08	Kishore Tipirneni	Bone screw system and method for the fixation of bone fractures
US8702768B2 (en)	2001-10-18	2014-04-22	Orthoip, Llc	Cannulated bone screw system and method
US20100268285A1 (en) *	2001-10-18	2010-10-21	Orthoip, Llc	Bone screw system and method for the fixation of bone fractures
US20080243191A1 (en) *	2001-10-18	2008-10-02	Fx Devices, Llc	Adjustable bone plate fixation system and metho
US20110034925A1 (en) *	2001-10-18	2011-02-10	Orthoip, Llc	Lagwire system and method for the fixation of bone fractures
US8828067B2 (en)	2001-10-18	2014-09-09	Orthoip, Llc	Bone screw system and method
US20090131991A1 (en) *	2001-10-18	2009-05-21	Kishore Tipirneni	System and method for the fixation of bone fractures
US6736819B2 (en) *	2001-10-18	2004-05-18	Kishore Tipirneni	System and method for fixation of bone fractures
US8679167B2 (en)	2001-10-18	2014-03-25	Orthoip, Llc	System and method for a cap used in the fixation of bone fractures
US20090048606A1 (en) *	2001-10-18	2009-02-19	Fxdevices Llc	Guide system and method for the fixation of bone fractures
US9060809B2 (en)	2001-10-18	2015-06-23	Orthoip, Llc	Lagwire system and method for the fixation of bone fractures
US6517889B1 (en)	2001-11-26	2003-02-11	Swaminathan Jayaraman	Process for coating a surface of a stent
US8454997B2 (en)	2001-12-18	2013-06-04	Novo Nordisk A/S	Solid dose micro implant
WO2003053493A2 (en)	2001-12-19	2003-07-03	Nmt Medical, Inc.	Septal occluder and associated methods
US7318833B2 (en)	2001-12-19	2008-01-15	Nmt Medical, Inc.	PFO closure device with flexible thrombogenic joint and improved dislodgement resistance
CA2471658A1 (en) *	2001-12-26	2003-07-10	Canon Kabushiki Kaisha	Probe medium and method for fixing probe on a substrate
US20030139819A1 (en) *	2002-01-18	2003-07-24	Beer Nicholas De	Method and apparatus for closing septal defects
EP1487353A4 (en)	2002-03-25	2008-04-16	Nmt Medical Inc	FORAMEN OVAL PERSISTENT CLOSURE CLAMPS (PFO)
US20040038303A1 (en) *	2002-04-08	2004-02-26	Unger Gretchen M.	Biologic modulations with nanoparticles
EP2075014B9 (en) *	2002-05-24	2012-02-01	Angiotech International Ag	Compositions and methods for coating medical implants
EP1509144A4 (en)	2002-06-03	2008-09-03	Nmt Medical Inc	DEVICE FOR REINFORCING BIOLOGICAL TISSUE FOR THE FILLING OF INTRACARDIAL FAULTS
WO2003103476A2 (en)	2002-06-05	2003-12-18	Nmt Medical, Inc.	Patent foramen ovale (pfo) closure device with radial and circumferential support
US7097850B2 (en) *	2002-06-18	2006-08-29	Surmodics, Inc.	Bioactive agent release coating and controlled humidity method
KR20050084599A (ko) *	2002-09-26	2005-08-26	안지오테크 인터내셔날 아게	혈관주위 랩
GB2393655B (en) *	2002-09-27	2005-08-24	Johnson & Johnson Medical Ltd	Wound treatment device
AU2003284976A1 (en)	2002-10-25	2004-05-13	Nmt Medical, Inc.	Expandable sheath tubing
US8034361B2 (en) *	2002-11-12	2011-10-11	Advanced Cardiovascular Systems, Inc.	Stent coatings incorporating nanoparticles
US7491234B2 (en) *	2002-12-03	2009-02-17	Boston Scientific Scimed, Inc.	Medical devices for delivery of therapeutic agents
WO2004052213A1 (en)	2002-12-09	2004-06-24	Nmt Medical, Inc.	Septal closure devices
JP5508661B2 (ja)	2003-02-12	2014-06-04	シンセラインコーポレイテッド	ランダムおよび非ランダムアルキレンオキシドポリマーアロイ組成物
US8715771B2 (en) *	2003-02-26	2014-05-06	Abbott Cardiovascular Systems Inc.	Coated stent and method of making the same
US7255891B1 (en) *	2003-02-26	2007-08-14	Advanced Cardiovascular Systems, Inc.	Method for coating implantable medical devices
US7658747B2 (en)	2003-03-12	2010-02-09	Nmt Medical, Inc.	Medical device for manipulation of a medical implant
WO2004098565A2 (en)	2003-05-02	2004-11-18	Surmodics, Inc.	Implantable controlled release bioactive agent delivery device
US8246974B2 (en)	2003-05-02	2012-08-21	Surmodics, Inc.	Medical devices and methods for producing the same
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
US9861346B2 (en)	2003-07-14	2018-01-09	W. L. Gore & Associates, Inc.	Patent foramen ovale (PFO) closure device with linearly elongating petals
WO2005006990A2 (en)	2003-07-14	2005-01-27	Nmt Medical, Inc.	Tubular patent foramen ovale (pfo) closure device with catch system
US8480706B2 (en)	2003-07-14	2013-07-09	W.L. Gore & Associates, Inc.	Tubular patent foramen ovale (PFO) closure device with catch system
US7169404B2 (en) *	2003-07-30	2007-01-30	Advanced Cardiovasular Systems, Inc.	Biologically absorbable coatings for implantable devices and methods for fabricating the same
US20050037047A1 (en) *	2003-08-11	2005-02-17	Young-Ho Song	Medical devices comprising spray dried microparticles
WO2005018728A2 (en)	2003-08-19	2005-03-03	Nmt Medical, Inc.	Expandable sheath tubing
US7807722B2 (en) *	2003-11-26	2010-10-05	Advanced Cardiovascular Systems, Inc.	Biobeneficial coating compositions and methods of making and using thereof
US20050273119A1 (en)	2003-12-09	2005-12-08	Nmt Medical, Inc.	Double spiral patent foramen ovale closure clamp
US8262694B2 (en)	2004-01-30	2012-09-11	W.L. Gore & Associates, Inc.	Devices, systems, and methods for closure of cardiac openings
EP1737349A1 (en)	2004-03-03	2007-01-03	NMT Medical, Inc.	Delivery/recovery system for septal occluder
US20050220853A1 (en) *	2004-04-02	2005-10-06	Kinh-Luan Dao	Controlled delivery of therapeutic agents from medical articles
US20050220841A1 (en)	2004-04-06	2005-10-06	Dewitt David M	Coating compositions for bioactive agents
US20050267524A1 (en)	2004-04-09	2005-12-01	Nmt Medical, Inc.	Split ends closure device
KR20070011469A (ko) *	2004-04-13	2007-01-24	알자 코포레이션	펜타닐계 약제의 경피전달용 장치 및 방법
US8361110B2 (en)	2004-04-26	2013-01-29	W.L. Gore & Associates, Inc.	Heart-shaped PFO closure device
US7842053B2 (en)	2004-05-06	2010-11-30	Nmt Medical, Inc.	Double coil occluder
US8308760B2 (en)	2004-05-06	2012-11-13	W.L. Gore & Associates, Inc.	Delivery systems and methods for PFO closure device with two anchors
US7704268B2 (en)	2004-05-07	2010-04-27	Nmt Medical, Inc.	Closure device with hinges
WO2005110240A1 (en)	2004-05-07	2005-11-24	Nmt Medical, Inc.	Catching mechanisms for tubular septal occluder
US20080249633A1 (en) *	2006-08-22	2008-10-09	Tim Wu	Biodegradable Materials and Methods of Use
US7767652B2 (en) *	2004-07-21	2010-08-03	Medtronic, Inc.	Medical devices and methods for reducing localized fibrosis
US20060030538A1 (en) *	2004-07-21	2006-02-09	Medtronic, Inc.	Methods for reducing or preventing localized fibrosis using SiRNA
US8980300B2 (en)	2004-08-05	2015-03-17	Advanced Cardiovascular Systems, Inc.	Plasticizers for coating compositions
US20060030539A1 (en) *	2004-08-06	2006-02-09	National Jewish Medical And Research Center	Product and process for inhibition of biofilm development
US20060057216A1 (en) *	2004-09-15	2006-03-16	Salamone Joseph C	Low-obscuration image transmitting particulate ocular therapeutic formulations
US20060057215A1 (en) *	2004-09-15	2006-03-16	Raiche Adrian T	Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7495052B2 (en) *	2004-09-15	2009-02-24	Bausch & Lomb Incorporated	Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
EP1827247B8 (en)	2004-09-24	2020-05-06	W.L. Gore & Associates, Inc.	Occluder device double securement system for delivery/recovery of such occluder device
CN101098703B (zh) *	2004-11-05	2011-08-03	费城儿童医院	用于分子治疗的生物降解连接剂
US8263105B2 (en) *	2004-12-01	2012-09-11	Tyco Healthcare Group Lp	Biomaterial drug delivery and surface modification compositions
CA2526541C (en) *	2004-12-01	2013-09-03	Tyco Healthcare Group Lp	Novel biomaterial drug delivery and surface modification compositions
WO2006063176A2 (en) *	2004-12-06	2006-06-15	The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services	Inhibition of biofilm formation using bacteriophage
US20060124466A1 (en) *	2004-12-09	2006-06-15	Scimed Life Systems, Inc.	Method and apparatus for coating a medical device by electroplating
JP4907643B2 (ja) *	2005-03-07	2012-04-04	ザリージェンツオブザユニバーシティオブカリフォルニア	医療用インプラント
WO2006102213A1 (en)	2005-03-18	2006-09-28	Nmt Medical, Inc.	Catch member for pfo occluder
ES2731298T3 (es)	2005-05-27	2019-11-14	Univ North Carolina Chapel Hill	Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
WO2007011708A2 (en)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Stent with polymer coating containing amorphous rapamycin
WO2007011707A2 (en)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Polymer coatings containing drug powder of controlled morphology
US20090118838A1 (en) *	2005-08-05	2009-05-07	Christian Debry	Materials Useful for Support and/or Replacement of Tissue and the Use Thereof for Making Prostheses
US7797056B2 (en)	2005-09-06	2010-09-14	Nmt Medical, Inc.	Removable intracardiac RF device
US9259267B2 (en)	2005-09-06	2016-02-16	W.L. Gore & Associates, Inc.	Devices and methods for treating cardiac tissue
US20070087059A1 (en) *	2005-10-17	2007-04-19	Frank Everaerts	Bioactive delivery matrix compositions and methods
CN1962155A (zh) *	2005-11-10	2007-05-16	鸿富锦精密工业（深圳）有限公司	一种二氧化碳激光焊接装置
CA2629600C (en)	2005-11-14	2011-11-01	Biomet 3I, Inc.	Deposition of discrete nanoparticles on an implant surface
US20070134191A1 (en) *	2005-12-14	2007-06-14	L'oreal	Hair styling compositions containing a nonionic amphiphilic polymer in combination with styling polymers and emulsifying agents
WO2007073566A1 (en)	2005-12-22	2007-06-28	Nmt Medical, Inc.	Catch members for occluder devices
US8663674B2 (en) *	2006-01-13	2014-03-04	Surmodics, Inc.	Microparticle containing matrices for drug delivery
US9108217B2 (en)	2006-01-31	2015-08-18	Nanocopoeia, Inc.	Nanoparticle coating of surfaces
US7951428B2 (en)	2006-01-31	2011-05-31	Regents Of The University Of Minnesota	Electrospray coating of objects
CA2641117C (en)	2006-01-31	2018-01-02	Nanocopoeia, Inc.	Nanoparticle coating of surfaces
EP2114298B1 (en)	2006-02-08	2022-10-19	Medtronic, Inc.	Temporarily stiffened mesh prostheses
US8591531B2 (en)	2006-02-08	2013-11-26	Tyrx, Inc.	Mesh pouches for implantable medical devices
US8315700B2 (en)	2006-02-08	2012-11-20	Tyrx, Inc.	Preventing biofilm formation on implantable medical devices
US8870913B2 (en)	2006-03-31	2014-10-28	W.L. Gore & Associates, Inc.	Catch system with locking cap for patent foramen ovale (PFO) occluder
CA2647505C (en)	2006-03-31	2014-07-29	Nmt Medical, Inc.	Deformable flap catch mechanism for occluder device
US8551135B2 (en)	2006-03-31	2013-10-08	W.L. Gore & Associates, Inc.	Screw catch mechanism for PFO occluder and method of use
CA2996768C (en)	2006-04-26	2020-12-08	Micell Technologies, Inc.	Coatings containing multiple drugs
US8017237B2 (en)	2006-06-23	2011-09-13	Abbott Cardiovascular Systems, Inc.	Nanoshells on polymers
US7638344B2 (en) *	2006-06-28	2009-12-29	Surmodics, Inc.	Active agent eluting matrices with particulates
WO2008005297A2 (en) *	2006-06-29	2008-01-10	Massachusetts Institute Of Technology	Coating of devices with effector compounds
EP3047860B1 (en)	2006-07-20	2024-08-28	OrbusNeich Medical Pte. Ltd.	Bioabsorbable polymeric composition for a medical device
US7833260B2 (en) *	2006-07-20	2010-11-16	Orbusneich Medical, Inc.	Bioabsorbable polymeric medical device
WO2008011612A2 (en)	2006-07-20	2008-01-24	Orbusneich Medical, Inc.	Bioabsorbable polymeric medical device
DE102006038240A1 (de) *	2006-08-07	2008-02-14	Biotronik Vi Patent Ag	Verfahren zur Herstellung eines Komposits aus Oligo- oder Polynucleotiden und hydrophoben biodegradierbaren Polymeren sowie nach dem Verfahren erhaltenes Komposit
WO2008042909A2 (en) *	2006-10-02	2008-04-10	Micell Technologies Inc.	Surgical sutures having increased strength
US8529958B2 (en)	2006-10-17	2013-09-10	Carmell Therapeutics Corporation	Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US7959942B2 (en) *	2006-10-20	2011-06-14	Orbusneich Medical, Inc.	Bioabsorbable medical device with coating
CN101563117B (zh) *	2006-10-20	2014-05-21	奥巴斯尼茨医学公司	具有包被层的可生物吸收的医疗设备
US8691321B2 (en) *	2006-10-20	2014-04-08	Orbusneich Medical, Inc.	Bioabsorbable polymeric composition and medical device background
CN101678388B (zh)	2006-10-23	2013-12-11	米歇尔技术公司	用于在涂覆过程中为基底充电的保持器
EP2079401B1 (en)	2006-10-24	2019-05-22	Biomet 3i, LLC	Deposition of discrete nanoparticles on a nanostructured surface of an implant
JP5227326B2 (ja) *	2006-11-03	2013-07-03	ボストンサイエンティフィックリミテッド	薬物を溶出する被覆を有するステント
MX2009004819A (es) *	2006-11-06	2009-11-23	Tyrx Pharma Inc	Bolsas reabsorbibles para dispositivos medicos implantables.
US9023114B2 (en)	2006-11-06	2015-05-05	Tyrx, Inc.	Resorbable pouches for implantable medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9040816B2 (en)	2006-12-08	2015-05-26	Nanocopoeia, Inc.	Methods and apparatus for forming photovoltaic cells using electrospray
CA2679712C (en)	2007-01-08	2016-11-15	Micell Technologies, Inc.	Stents having biodegradable layers
US11426494B2 (en)	2007-01-08	2022-08-30	MT Acquisition Holdings LLC	Stents having biodegradable layers
US8753662B2 (en) *	2007-02-15	2014-06-17	National Jewish Health	Methods and compositions for the disruption of biofilms
WO2008115978A2 (en) *	2007-03-20	2008-09-25	University Of Florida Research Foundation, Inc.	Polymer with ability to signal the recruitment of vascular progenitor cells
AU2008232682B2 (en) *	2007-03-29	2013-03-21	Medtronic, Inc.	Biodegradable, polymer coverings for breast implants
US8178483B2 (en) *	2007-03-30	2012-05-15	Colgate-Palmolive Company	Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
WO2008124603A1 (en)	2007-04-05	2008-10-16	Nmt Medical, Inc.	Septal closure device with centering mechanism
BRPI0810370A2 (pt) *	2007-04-17	2014-10-29	Micell Technologies Inc	Stent revestido, e, método para preparar um stent
US9138562B2 (en)	2007-04-18	2015-09-22	W.L. Gore & Associates, Inc.	Flexible catheter system
US8309222B2 (en) *	2007-04-25	2012-11-13	Covidien Lp	Coated filaments
US20100069957A1 (en) *	2007-04-25	2010-03-18	Ferass Abuzaina	Coated Filaments
WO2008148013A1 (en)	2007-05-25	2008-12-04	Micell Technologies, Inc.	Polymer films for medical device coating
US8802184B2 (en)	2007-05-30	2014-08-12	Abbott Cardiovascular Systems Inc.	Medical devices containing biobeneficial particles
US8133553B2 (en)	2007-06-18	2012-03-13	Zimmer, Inc.	Process for forming a ceramic layer
US8309521B2 (en)	2007-06-19	2012-11-13	Zimmer, Inc.	Spacer with a coating thereon for use with an implant device
US8048441B2 (en) *	2007-06-25	2011-11-01	Abbott Cardiovascular Systems, Inc.	Nanobead releasing medical devices
US20090004243A1 (en)	2007-06-29	2009-01-01	Pacetti Stephen D	Biodegradable triblock copolymers for implantable devices
US20100094405A1 (en) *	2008-10-10	2010-04-15	Orbusneich Medical, Inc.	Bioabsorbable Polymeric Medical Device
US20110130822A1 (en) *	2007-07-20	2011-06-02	Orbusneich Medical, Inc.	Bioabsorbable Polymeric Compositions and Medical Devices
US8865216B2 (en) *	2007-08-03	2014-10-21	National Institutes Of Health (Nih)	Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
US20090041727A1 (en) *	2007-08-08	2009-02-12	Conjugon, Inc.	Compositions and Methods for Microbe Storage and Delivery
US20110230973A1 (en) *	2007-10-10	2011-09-22	Zimmer, Inc.	Method for bonding a tantalum structure to a cobalt-alloy substrate
US8608049B2 (en) *	2007-10-10	2013-12-17	Zimmer, Inc.	Method for bonding a tantalum structure to a cobalt-alloy substrate
US8661630B2 (en) *	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
EP2997985A1 (en)	2007-10-30	2016-03-23	Nanyang Technological University	A non-biodegradable stent comprising a biodegradable coating and method of coating the same
US8642062B2 (en)	2007-10-31	2014-02-04	Abbott Cardiovascular Systems Inc.	Implantable device having a slow dissolving polymer
US9308068B2 (en)	2007-12-03	2016-04-12	Sofradim Production	Implant for parastomal hernia
US20090187256A1 (en) *	2008-01-21	2009-07-23	Zimmer, Inc.	Method for forming an integral porous region in a cast implant
EP2240116B1 (en)	2008-01-28	2015-07-01	Biomet 3I, LLC	Implant surface with increased hydrophilicity
US20090198286A1 (en) *	2008-02-05	2009-08-06	Zimmer, Inc.	Bone fracture fixation system
US20130165967A1 (en)	2008-03-07	2013-06-27	W.L. Gore & Associates, Inc.	Heart occlusion devices
US8951545B2 (en)	2008-03-28	2015-02-10	Surmodics, Inc.	Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
SG192523A1 (en)	2008-04-17	2013-08-30	Micell Technologies Inc	Stents having bioabsorbable layers
US20090285873A1 (en) *	2008-04-18	2009-11-19	Abbott Cardiovascular Systems Inc.	Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide)
US8496954B2 (en) *	2008-04-18	2013-07-30	Surmodics, Inc.	Coating systems for the controlled delivery of hydrophilic bioactive agents
US8916188B2 (en) *	2008-04-18	2014-12-23	Abbott Cardiovascular Systems Inc.	Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US8697113B2 (en)	2008-05-21	2014-04-15	Abbott Cardiovascular Systems Inc.	Coating comprising a terpolymer comprising caprolactone and glycolide
US9242026B2 (en)	2008-06-27	2016-01-26	Sofradim Production	Biosynthetic implant for soft tissue repair
EP2313122B1 (en)	2008-07-17	2019-03-06	Micell Technologies, Inc.	Drug delivery medical device
US9510856B2 (en)	2008-07-17	2016-12-06	Micell Technologies, Inc.	Drug delivery medical device
US9295820B2 (en) *	2008-08-14	2016-03-29	Surmodics, Inc.	Method and apparatus for coating balloon catheters
US8226603B2 (en)	2008-09-25	2012-07-24	Abbott Cardiovascular Systems Inc.	Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8076529B2 (en)	2008-09-26	2011-12-13	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8500687B2 (en)	2008-09-25	2013-08-06	Abbott Cardiovascular Systems Inc.	Stent delivery system having a fibrous matrix covering with improved stent retention
US8049061B2 (en)	2008-09-25	2011-11-01	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
FR2936709B1 (fr) *	2008-10-02	2012-05-11	Ethypharm Sa	Comprimes alcoolo-resistants.
CN102245125A (zh) *	2008-10-11	2011-11-16	奥巴斯尼茨医学公司	生物可吸收聚合物组合物和医疗器材
EP2334279A4 (en) *	2008-10-16	2013-03-20	Novan Inc	STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
US8834913B2 (en)	2008-12-26	2014-09-16	Battelle Memorial Institute	Medical implants and methods of making medical implants
WO2010120552A2 (en)	2009-04-01	2010-10-21	Micell Technologies, Inc.	Coated stents
WO2010121187A2 (en)	2009-04-17	2010-10-21	Micell Techologies, Inc.	Stents having controlled elution
US8697110B2 (en)	2009-05-14	2014-04-15	Abbott Cardiovascular Systems Inc.	Polymers comprising amorphous terpolymers and semicrystalline blocks
US20120029556A1 (en)	2009-06-22	2012-02-02	Masters Steven J	Sealing device and delivery system
US9636094B2 (en)	2009-06-22	2017-05-02	W. L. Gore & Associates, Inc.	Sealing device and delivery system
KR101026513B1 (ko)	2009-08-14	2011-04-01	한국과학기술원	수산화 벤젠-아민계 화합물을 이용하여 표면이 개질된 고체 기판 및 이를 이용한 고체 기판의 표면개질 방법
WO2011022652A1 (en)	2009-08-21	2011-02-24	Novan, Inc.	Topical gels
CA2771389C (en)	2009-08-21	2019-04-09	Novan, Inc.	Wound dressings, methods of using the same and methods of forming the same
FR2949688B1 (fr)	2009-09-04	2012-08-24	Sofradim Production	Tissu avec picots revetu d'une couche microporeuse bioresorbable
BR112012008508A2 (pt) *	2009-10-13	2017-06-13	Novan Inc	revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
US10905405B2 (en)	2009-12-17	2021-02-02	Nanyang Technological University	Occlusion device for closing anatomical defects
US11369498B2 (en)	2010-02-02	2022-06-28	MT Acquisition Holdings LLC	Stent and stent delivery system with improved deliverability
WO2011096896A1 (en)	2010-02-05	2011-08-11	Nanyang Technological University	Occlusion device for closing anatomical defects
US8795762B2 (en)	2010-03-26	2014-08-05	Battelle Memorial Institute	System and method for enhanced electrostatic deposition and surface coatings
US8641418B2 (en)	2010-03-29	2014-02-04	Biomet 3I, Llc	Titanium nano-scale etching on an implant surface
CA2797110C (en)	2010-04-22	2020-07-21	Micell Technologies, Inc.	Stents and other devices having extracellular matrix coating
RS56011B1 (sr)	2010-04-29	2017-09-29	Ionis Pharmaceuticals Inc	Modulacija ekspresije transtiretina
US20110293690A1 (en) *	2010-05-27	2011-12-01	Tyco Healthcare Group Lp	Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
WO2012003293A1 (en)	2010-06-30	2012-01-05	Surmodics, Inc.	Lipid coating for medical devices delivering bioactive agent
US9295663B2 (en)	2010-07-14	2016-03-29	Abbott Cardiovascular Systems Inc.	Drug coated balloon with in-situ formed drug containing microspheres
EP2593039B1 (en)	2010-07-16	2022-11-30	Micell Technologies, Inc.	Drug delivery medical device
US8716204B2 (en)	2010-07-27	2014-05-06	Zimmer, Inc.	Synthetic synovial fluid compositions and methods for making the same
AU2011326417A1 (en)	2010-11-12	2013-05-09	Tyrx, Inc.	Anchorage devices comprising an active pharmaceutical ingredient
US8591876B2 (en)	2010-12-15	2013-11-26	Novan, Inc.	Methods of decreasing sebum production in the skin
WO2012118829A2 (en)	2011-02-28	2012-09-07	Novan, Inc.	Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
FR2972626B1 (fr)	2011-03-16	2014-04-11	Sofradim Production	Prothese comprenant un tricot tridimensionnel et ajoure
US10464100B2 (en)	2011-05-31	2019-11-05	Micell Technologies, Inc.	System and process for formation of a time-released, drug-eluting transferable coating
WO2012177825A1 (en)	2011-06-21	2012-12-27	Bvw Holding Ag	Medical device comprising boswellic acid
FR2977789B1 (fr)	2011-07-13	2013-07-19	Sofradim Production	Prothese pour hernie ombilicale
FR2977790B1 (fr)	2011-07-13	2013-07-19	Sofradim Production	Prothese pour hernie ombilicale
EP2731510B1 (en)	2011-07-15	2021-04-21	Nanyang Technological University	Occlusion device for closing anatomical defects
US10117972B2 (en)	2011-07-15	2018-11-06	Micell Technologies, Inc.	Drug delivery medical device
US9770232B2 (en)	2011-08-12	2017-09-26	W. L. Gore & Associates, Inc.	Heart occlusion devices
CA2849052C (en)	2011-09-30	2019-11-05	Sofradim Production	Reversible stiffening of light weight mesh
US10188772B2 (en)	2011-10-18	2019-01-29	Micell Technologies, Inc.	Drug delivery medical device
FR2985170B1 (fr)	2011-12-29	2014-01-24	Sofradim Production	Prothese pour hernie inguinale
FR2985271B1 (fr)	2011-12-29	2014-01-24	Sofradim Production	Tricot a picots
US9131995B2 (en)	2012-03-20	2015-09-15	Biomet 3I, Llc	Surface treatment for an implant surface
CA2874824C (en)	2012-06-01	2021-10-26	Surmodics, Inc.	Apparatus and methods for coating balloon catheters
US9827401B2 (en)	2012-06-01	2017-11-28	Surmodics, Inc.	Apparatus and methods for coating medical devices
FR2994185B1 (fr)	2012-08-02	2015-07-31	Sofradim Production	Procede de preparation d’une couche poreuse a base de chitosane
US8894563B2 (en)	2012-08-10	2014-11-25	Attenuex Technologies, Inc.	Methods and systems for performing a medical procedure
FR2995788B1 (fr)	2012-09-25	2014-09-26	Sofradim Production	Patch hemostatique et procede de preparation
FR2995779B1 (fr)	2012-09-25	2015-09-25	Sofradim Production	Prothese comprenant un treillis et un moyen de consolidation
FR2995778B1 (fr)	2012-09-25	2015-06-26	Sofradim Production	Prothese de renfort de la paroi abdominale et procede de fabrication
CA2880380C (en)	2012-09-28	2020-09-15	Sofradim Production	Packaging for a hernia repair device
US10828019B2 (en)	2013-01-18	2020-11-10	W.L. Gore & Associates, Inc.	Sealing device and delivery system
US10076331B2 (en)	2013-02-01	2018-09-18	Nanyang Technological University	Device and method for forming an anastomotic joint between two parts of a body
US11439690B2 (en)	2013-02-07	2022-09-13	The Cleveland Clinic Foundation	Methods of treating spinal cord injury
US9951374B2 (en)	2013-02-19	2018-04-24	Wisconsin Alumni Research Foundation	Enhanced throughput mineral coatings for optimization of stem cell behavior
AU2014248508B2 (en)	2013-03-12	2018-11-08	Micell Technologies, Inc.	Bioabsorbable biomedical implants
WO2014186532A1 (en)	2013-05-15	2014-11-20	Micell Technologies, Inc.	Bioabsorbable biomedical implants
FR3006578B1 (fr)	2013-06-07	2015-05-29	Sofradim Production	Prothese a base d’un textile pour voie laparoscopique
FR3006581B1 (fr)	2013-06-07	2016-07-22	Sofradim Production	Prothese a base d’un textile pour voie laparoscopique
US9808230B2 (en)	2014-06-06	2017-11-07	W. L. Gore & Associates, Inc.	Sealing device and delivery system
CA2959660A1 (en)	2014-09-03	2016-03-10	Genesegues, Inc.	Therapeutic nanoparticles and related compositions, methods, and systems
EP3000433B1 (en)	2014-09-29	2022-09-21	Sofradim Production	Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis
EP3000432B1 (en)	2014-09-29	2022-05-04	Sofradim Production	Textile-based prosthesis for treatment of inguinal hernia
EP3029189B1 (en)	2014-12-05	2021-08-11	Sofradim Production	Prosthetic porous knit, method of making same and hernia prosthesis
EP3229855B1 (en) *	2014-12-09	2024-05-08	The Regents of the University of California	Novel wound-healing-enhancing devices
US20170182207A1 (en) *	2014-12-09	2017-06-29	The Regents Of The University Of California	Wound-healing-enhancing devices
EP3232961B1 (en)	2014-12-15	2022-06-08	Smith & Nephew, Inc.	Active fracture compression implants
EP3059255B1 (en)	2015-02-17	2020-05-13	Sofradim Production	Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
EP3085337B1 (en)	2015-04-24	2022-09-14	Sofradim Production	Prosthesis for supporting a breast structure
US11439609B2 (en) *	2015-06-11	2022-09-13	The Regents Of The University Of Michigan	Nitric oxide releasing PLGA microspheres for biomedical applications
EP3106185B1 (en)	2015-06-19	2018-04-25	Sofradim Production	Synthetic prosthesis comprising a knit and a non porous film and method for forming same
CN104984386A (zh) *	2015-07-20	2015-10-21	太原理工大学	一种载药聚乳酸手术缝合线的制备方法
EP3195830B1 (en)	2016-01-25	2020-11-18	Sofradim Production	Prosthesis for hernia repair
EP3210572A1 (en) *	2016-02-29	2017-08-30	Elodie Jane Siney	Intraocular lens comprising drug-containing microspheres
EP3312325B1 (en)	2016-10-21	2021-09-22	Sofradim Production	Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
WO2018183389A1 (en) *	2017-03-28	2018-10-04	Allied Bioscience, Inc.	Antimicrobial coatings for medical implements and medical devices
EP3398554B1 (en)	2017-05-02	2025-06-25	Sofradim Production	Prosthesis for inguinal hernia repair
EP3653171B1 (en)	2018-11-16	2024-08-21	Sofradim Production	Implants suitable for soft tissue repair
WO2020112816A1 (en)	2018-11-29	2020-06-04	Surmodics, Inc.	Apparatus and methods for coating medical devices
US20200254226A1 (en)	2019-02-07	2020-08-13	Solace Therapeutics, Inc.	Pressure attenuation device
US11819590B2 (en)	2019-05-13	2023-11-21	Surmodics, Inc.	Apparatus and methods for coating medical devices
CN110141676A (zh) *	2019-05-27	2019-08-20	南通大学附属医院	可表征药物控释效果的医用缝线及其制备方法
US12064330B2 (en)	2020-04-28	2024-08-20	Covidien Lp	Implantable prothesis for minimally invasive hernia repair
US12496612B2 (en)	2021-01-08	2025-12-16	Surmodics, Inc.	Coating application system and methods for coating rotatable medical devices

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL290280A (2) *	1962-03-15
US3557795A (en) *	1968-06-19	1971-01-26	Weck & Co Inc Edward	Suture provided with wound healing coating
US3839297A (en) *	1971-11-22	1974-10-01	Ethicon Inc	Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4351337A (en) *	1973-05-17	1982-09-28	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4024871A (en) *	1975-07-23	1977-05-24	Ethicon, Inc.	Antimicrobial sutures
CH653558A5 (fr) *	1979-11-23	1986-01-15	Battelle Memorial Institute	Fil de suture muni d'un manchon protecteur.
US4534958A (en) *	1983-07-13	1985-08-13	Basf Wyandotte Corporation	Aerosol gel
US4563489A (en) *	1984-02-10	1986-01-07	University Of California	Biodegradable organic polymer delivery system for bone morphogenetic protein
US4532929A (en) *	1984-07-23	1985-08-06	Ethicon, Inc.	Dry coating of surgical filaments
ATE61935T1 (de) *	1985-02-07	1991-04-15	Takeda Chemical Industries Ltd	Verfahren zur herstellung von mikrokapseln.
US5225279A (en) *	1985-04-30	1993-07-06	Rohm And Haas Company	Solvent core encapsulant composition
US4649920A (en) *	1986-01-30	1987-03-17	Pfizer Hospital Products Group, Inc.	Coated suture
US5032638A (en) *	1986-09-05	1991-07-16	American Cyanamid Company	Bioabsorbable coating for a surgical device
US4711241A (en) *	1986-09-05	1987-12-08	American Cyanamid Company	Surgical filament coating
US4857602A (en) *	1986-09-05	1989-08-15	American Cyanamid Company	Bioabsorbable surgical suture coating
JPS63130069A (ja) *	1986-11-21	1988-06-02	テルモ株式会社	医療用材料およびその製造方法
EP0336964B1 (en) *	1986-12-03	1993-08-04	Terumo Kabushiki Kaisha	Antithrombotic medical materials and process for their production
JPS6485660A (en) *	1987-02-19	1989-03-30	Nippon Medical Supply	Suture coated with sugar fatty acid ester
US4968350A (en) *	1987-04-16	1990-11-06	Christian Bindschaedler	Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof
US5306289A (en) *	1987-08-26	1994-04-26	United States Surgical Corporation	Braided suture of improved characteristics
US5123912A (en) *	1987-08-26	1992-06-23	United States Surgical Corporation	Absorbable coating composition, coated sutures and method of preparation
US4846844A (en) *	1987-08-31	1989-07-11	Eli Lilly And Company	Antimicrobial coated implants
US4898734A (en) *	1988-02-29	1990-02-06	Massachusetts Institute Of Technology	Polymer composite for controlled release or membrane formation
JPH01223969A (ja) *	1988-03-04	1989-09-07	Nippon Medical Supply Corp	被覆縫合糸
JP2561309B2 (ja) *	1988-03-28	1996-12-04	テルモ株式会社	医療用材料およびその製造方法
US5843156A (en) *	1988-08-24	1998-12-01	Endoluminal Therapeutics, Inc.	Local polymeric gel cellular therapy
US5470829A (en) *	1988-11-17	1995-11-28	Prisell; Per	Pharmaceutical preparation
US5162430A (en) *	1988-11-21	1992-11-10	Collagen Corporation	Collagen-polymer conjugates
ES2055112T3 (es) *	1988-12-29	1994-08-16	Deknatel Tech Corp	Revestimiento y mezcla absorbibles.
US5514550A (en) *	1989-02-03	1996-05-07	Johnson & Johnson Clinical Diagnostics, Inc.	Nucleic acid test article and its use to detect a predetermined nucleic acid
US5008334A (en) *	1989-02-28	1991-04-16	Basf Corporation	Resins of epoxy/aromatic diol copolymer and block copolymer of epoxy/aromatic diol copolymer and a epoxy-capped polybutadiene (co)polymer
US5698531A (en) *	1989-03-31	1997-12-16	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5292522A (en) *	1989-06-20	1994-03-08	Rohm Gmbh	Aqueous film coating agent for solid medicaments
FR2649321A1 (fr) *	1989-07-07	1991-01-11	Inst Nat Sante Rech Med	Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
US5723119A (en) *	1989-07-28	1998-03-03	Schering Corporation	Method for enhancing wound healing/repair with IL-4
IL95952A0 (en) *	1989-10-19	1991-07-18	Sterling Drug Inc	Aerosol composition for topical medicament
WO1991006286A1 (en) *	1989-11-06	1991-05-16	Enzytech, Inc.	Method for producing protein microspheres
US5271961A (en) *	1989-11-06	1993-12-21	Alkermes Controlled Therapeutics, Inc.	Method for producing protein microspheres
WO1991006287A1 (en) *	1989-11-06	1991-05-16	Enzytech, Inc.	Protein microspheres and methods of using them
US5674192A (en) *	1990-12-28	1997-10-07	Boston Scientific Corporation	Drug delivery
US5304121A (en) *	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5258436A (en) *	1989-12-19	1993-11-02	Fmc Corporation	Film-forming composition; method of producing same and use for coating pharmaceuticals and foods and the like
US5147383A (en) *	1990-02-01	1992-09-15	Ethicon, Inc.	Suture coated with a polyvinyl ester
MY107937A (en) *	1990-02-13	1996-06-29	Takeda Chemical Industries Ltd	Prolonged release microcapsules.
US5478564A (en) *	1990-02-22	1995-12-26	Teva Pharmaceutical Industries, Ltd.	Preparation of microparticles for controlled release of water-soluble substances
WO1991015260A1 (en) *	1990-03-30	1991-10-17	Alza Corporation	Device and method for iontophoretic drug delivery
FR2660556B1 (fr) *	1990-04-06	1994-09-16	Rhone Poulenc Sante	Microspheres, leur procede de preparation et leur utilisation.
US5290271A (en) *	1990-05-14	1994-03-01	Jernberg Gary R	Surgical implant and method for controlled release of chemotherapeutic agents
US5460831A (en) *	1990-06-22	1995-10-24	The Regents Of The University Of California	Targeted transfection nanoparticles
US5100433A (en) *	1990-11-08	1992-03-31	Ethicon, Inc.	Suture coated with a copolymer coating composition
US5102420A (en) *	1990-11-14	1992-04-07	Ethicon, Inc.	Suture coated with a polyetheramide
US5102402A (en) *	1991-01-04	1992-04-07	Medtronic, Inc.	Releasable coatings on balloon catheters
NZ242065A (en) *	1991-03-26	1996-06-25	Csl Ltd	Delayed release implant having a degradable or rupturable polymeric coating
CA2084194C (en) *	1991-04-02	2003-05-20	Gregory John Russell-Jones	Oral delivery systems for microparticles
DE4120760A1 (de) *	1991-06-24	1993-03-04	3 M Medica Gmbh	Traegersysteme fuer arzneimittel
CA2082411A1 (en) *	1991-06-28	1992-12-29	Robert D. Rosenberg	Localized oligonucleotide therapy
ES2034891B1 (es) *	1991-08-08	1993-12-16	Cusi Lab	Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
WO1993007924A1 (en) *	1991-10-18	1993-04-29	Spire Corporation	Bactericidal coatings for implants
US5298422A (en) *	1991-11-06	1994-03-29	Baylor College Of Medicine	Myogenic vector systems
AU3664693A (en) *	1992-02-13	1993-09-03	Bio-Metric Systems, Inc.	Immobilization of chemical species in crosslinked matrices
US5225485A (en) *	1992-03-03	1993-07-06	United States Surgical Corporation	Polyetherimide ester suture and its method of manufacture and method of use
US5792751A (en) *	1992-04-13	1998-08-11	Baylor College Of Medicine	Tranformation of cells associated with fluid spaces
FI91713C (fi) *	1992-04-23	1994-08-10	Axidental Oy	Uusia bioaktiivisia pinnotteita ja niiden valmistus ja käyttö
US6197346B1 (en) *	1992-04-24	2001-03-06	Brown Universtiy Research Foundation	Bioadhesive microspheres and their use as drug delivery and imaging systems
US5312437A (en) *	1992-06-12	1994-05-17	United States Surgical Corporation	Absorbable coating composition and suture coated therewith
WO1994012629A1 (en) *	1992-12-02	1994-06-09	Baylor College Of Medicine	Episomal vectors for gene therapy
TW333456B (en) *	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
ATE167396T1 (de) *	1993-02-22	1998-07-15	Alza Corp	Mittel zur oralen gabe von wirkstoffen
NZ265555A (en) *	1993-04-19	1997-09-22	Medisorb Technologies Internat	Biodegradable microparticle compositions of antisense oligodeoxyribonucleotides
US5464650A (en) *	1993-04-26	1995-11-07	Medtronic, Inc.	Intravascular stent and method
EP1155689B1 (en) *	1993-07-19	2006-09-20	Angiotech Pharmaceuticals, Inc.	Anti-angiogenic stents and methods of their preparation
US5962427A (en) *	1994-02-18	1999-10-05	The Regent Of The University Of Michigan	In vivo gene transfer methods for wound healing
DE69529054T2 (de) *	1994-02-28	2003-08-21	Nanopharm Ag	System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
EP0804249A2 (en) *	1994-03-15	1997-11-05	Brown University Research Foundation	Polymeric gene delivery system
US5480963A (en) *	1994-07-22	1996-01-02	United States Surgical Corporation	Absorbable copolymers derived from tricarboxylic acids and surgical articles made therefrom
US5652225A (en) *	1994-10-04	1997-07-29	St. Elizabeth's Medical Center Of Boston, Inc.	Methods and products for nucleic acid delivery
JPH10509696A (ja) *	1994-10-12	1998-09-22	フォーカル，インコーポレイテッド	生分解性ポリマーを介する標的化送達
US5545135A (en) *	1994-10-31	1996-08-13	Boston Scientific Corporation	Perfusion balloon stent
US5830879A (en) *	1995-10-02	1998-11-03	St. Elizabeth's Medical Center Of Boston, Inc.	Treatment of vascular injury using vascular endothelial growth factor
US6143037A (en) *	1996-06-12	2000-11-07	The Regents Of The University Of Michigan	Compositions and methods for coating medical devices
US6395029B1 (en) *	1999-01-19	2002-05-28	The Children's Hospital Of Philadelphia	Sustained delivery of polyionic bioactive agents

1996
- 1996-06-12 US US08/662,341 patent/US6143037A/en not_active Expired - Fee Related
1997
- 1997-06-11 IL IL153374A patent/IL153374A/en not_active IP Right Cessation
- 1997-06-11 IL IL12744697A patent/IL127446A/xx not_active IP Right Cessation
- 1997-06-11 CA CA002257976A patent/CA2257976C/en not_active Expired - Fee Related
- 1997-06-11 JP JP10501785A patent/JP2000512519A/ja active Pending
- 1997-06-11 EP EP97929915A patent/EP0910301A4/en not_active Withdrawn
- 1997-06-11 AU AU33866/97A patent/AU715339B2/en not_active Ceased
- 1997-06-11 WO PCT/US1997/010079 patent/WO1997047254A1/en not_active Ceased
2005
- 2005-02-28 US US11/068,735 patent/US20060035854A1/en not_active Abandoned
2009
- 2009-02-04 JP JP2009023612A patent/JP2009102418A/ja active Pending

Also Published As

Publication number	Publication date
IL127446A0 (en)	1999-10-28
US20060035854A1 (en)	2006-02-16
AU3386697A (en)	1998-01-07
WO1997047254A1 (en)	1997-12-18
AU715339B2 (en)	2000-01-20
JP2009102418A (ja)	2009-05-14
IL127446A (en)	2003-07-06
CA2257976C (en)	2008-01-15
EP0910301A4 (en)	2004-10-27
JP2000512519A (ja)	2000-09-26
EP0910301A1 (en)	1999-04-28
US6143037A (en)	2000-11-07
CA2257976A1 (en)	1997-12-18

Legal Events

Date	Code	Title	Description
2015-06-30	KB	Patent renewed
2018-01-31	EXP	Patent expired

Publication	Publication Date	Title
AU715339B2 (en)	2000-01-20	Compositions and methods for coating medical devices
WO1997047254A9 (en)	1998-03-19	Compositions and methods for coating medical devices
Lincoff et al.	1994	Local drug delivery for the prevention of restenosis. Fact, fancy, and future.
US6814980B2 (en)	2004-11-09	Microspheres containing condensed polyanionic bioactive agents and methods for their production
EP0805678B1 (en)	2003-10-29	Surface-modified nanoparticles and method of making and using same
US7820732B2 (en)	2010-10-26	Methods for modulating thermal and mechanical properties of coatings on implantable devices
US6395029B1 (en)	2002-05-28	Sustained delivery of polyionic bioactive agents
Prestwich et al.	2001	Novel biomaterials for drug delivery
US20150142026A1 (en)	2015-05-21	Therapeutic electrospun fiber compositions
US20060024350A1 (en)	2006-02-02	Biodegradable ocular devices, methods and systems
WO2001040272A2 (en)	2001-06-07	In situ bioreactors and methods of use thereof
JP2003527158A (ja)	2003-09-16	生体適合性医療装置
EP1023005B1 (en)	2009-08-05	Stent coated with dna
US20230381255A1 (en)	2023-11-30	Therapeutic viral microparticles for promoting stent biofunctionality and wound healing in vertebrate individuals
AU1845100A (en)	2000-06-22	Surface modified nanoparticles and method of making and using same
HK1091840B (en)	2009-05-29	Methods and compositions for therapeutic use of rna interference